Grant: Alliance Grants
Université de Montréal
$60,708.00
Engineering Natural Killer Cells to Increase their Potency _x000d_
EF 2020-21
Résumé
The immune system has evolved to specifically recognize, target and kill infection and malignant cells. However, in several severe diseases, its capacity is dampened by the infectious agent or the tumor environment, limiting its scope of efficacy. For example, the severity of COVID-19 disease has been associated with a decreased number of immune cytotoxic cells, and these cells were found to be exhausted, meaning that they could no longer do their role in an effective way. In this proposal, we propose to apply state-of-the-art gene and cell engineering to the immune system to create tools that could be used to control viral infections or cancer. Natural Killer (NK) cells, which are white blood cells specialized in detection and elimination of viral infected cells and malignant cells, are interesting cell candidate to harness as they are safe and they can be administered regardless the compatibility of the donor. Hence, it would be interesting to modify them to enhance their potency. However, NK cells are notoriously difficult to engineer. To circumvent this issue, we have built a team of academic researchers in cell engineering and a Canadian biotechnology company, Feldan Therapeutics. Our team develops techniques to engineer NK cells to be more resistant to exhaustion (Feldan Therapeutic's technology) and to make them recognize more efficiently malignant cells or cells infected by virus, such as the SARS-CoV-2 (Dr. Haddad's laboratory's technology). In this project, we will devise innovative ways to create a new generation of engineered NK cells with increased potency and we will test the impact of these modifications on their function, survival and safety. If proven effective, this technology would be versatile and could significantly impact Feldan's business strategy by positioning the company as a leader in cell-based immuno-oncology by providing a breakthrough technology based on their Shuttle technology.
_x000d_Le système immunitaire a évolué de façon à identifier, cibler et tuer des cellules infectées ou transformées. Toutefois, cette capacité est réduite par certains agents infectieux ou encore des cellules tumorales, contribuant ainsi à la sévérité de plusieu
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
560412-2020
Name nom
Haddad, Elie
Department département
Pédiatrie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
60708
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Engineering Natural Killer Cells to Increase their Potency _x000d_
Keyword
NSERC
Application summary
The immune system has evolved to specifically recognize, target and kill infection and malignant cells. However, in several severe diseases, its capacity is dampened by the infectious agent or the tumor environment, limiting its scope of efficacy. For example, the severity of COVID-19 disease has been associated with a decreased number of immune cytotoxic cells, and these cells were found to be exhausted, meaning that they could no longer do their role in an effective way. In this proposal, we propose to apply state-of-the-art gene and cell engineering to the immune system to create tools that could be used to control viral infections or cancer. Natural Killer (NK) cells, which are white blood cells specialized in detection and elimination of viral infected cells and malignant cells, are interesting cell candidate to harness as they are safe and they can be administered regardless the compatibility of the donor. Hence, it would be interesting to modify them to enhance their potency. However, NK cells are notoriously difficult to engineer. To circumvent this issue, we have built a team of academic researchers in cell engineering and a Canadian biotechnology company, Feldan Therapeutics. Our team develops techniques to engineer NK cells to be more resistant to exhaustion (Feldan Therapeutic's technology) and to make them recognize more efficiently malignant cells or cells infected by virus, such as the SARS-CoV-2 (Dr. Haddad's laboratory's technology). In this project, we will devise innovative ways to create a new generation of engineered NK cells with increased potency and we will test the impact of these modifications on their function, survival and safety. If proven effective, this technology would be versatile and could significantly impact Feldan's business strategy by positioning the company as a leader in cell-based immuno-oncology by providing a breakthrough technology based on their Shuttle technology.
_x000d_Le système immunitaire a évolué de façon à identifier, cibler et tuer des cellules infectées ou transformées. Toutefois, cette capacité est réduite par certains agents infectieux ou encore des cellules tumorales, contribuant ainsi à la sévérité de plusieu